VERY GOOD NEWS
Psybio Therapeutics added to AdvisorShares Psychedelics
2021-09-17 09:25 ET - News Release
Mr. Evan Levine reports
PSYBIO THERAPEUTICS ANNOUNCES INCLUSION IN NYSE LISTED ADVISORSHARES PSYCHEDELICS EXCHANGE TRADED FUND
Psybio Therapeutics Corp. has been included in the AdvisorShares Psychedelics ETF (exchange-traded fund).
The ETF will actively manage investments in the emerging psychedelic drugs sector, offering exposure to those biotechnology, pharmaceutical and life sciences companies that the ETF sees as leading the industry. The ETF currently includes 16 psychedelics companies and is listed on the NYSE Arca under the ticker symbol (NYSE: PSIL).
Evan Levine, Chief Executive Officer and Chairman of PsyBio, said, "The inclusion of PsyBio in AdvisorShares Psychedelics ETF recognizes us as a leader in the psychedelics industry, as we continue to research and develop innovative treatments to potentially improve mental and neurological health. We want to thank AdvisorShares for this recognition, which is a testament to the work the Company is advancing in this area. We are proud to be included in the ETF and look forward to continuing engagement with investors on the development of PsyBio's therapeutics program to treat specific clinical conditions."
Additional information on the AdvisorShares Psychedelics ETF can be found here.
About PsyBio Therapeutics Corp.
PsyBio Therapeutics is an intellectual property driven biotechnology company developing novel, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health. The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company utilizes a Bio Medicinal Chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.